Sacituzumab Govitecan Plus Pembrolizumab Promising for Metastatic Urothelial Cancer After Failure With Platinum-Based Regimen
Cohort 3 of the phase 2 TROPHY-U-01 trial evaluated sacituzumab govitecan plus pembrolizumab in checkpoint inhibitor-naive adults with metastatic urothelial cancer who progressed after platinum-based chemotherapy.